Localization of SARS-CoV-2 proteins and vaccine mRNA in LNs
(A) Representative LN GC after mRNA vaccination showing hematoxylin and eosin staining (upper left), four-color Codex staining (lower left), in situ hybridization of a SARS-CoV-2 mRNA vaccine-specific probe (upper right [lower magnification] and middle right [greater magnification]), and immunohistochemical (IHC) staining for spike antigen (lower right). Vaccine mRNA probe hybridization was visualized by colorimetric development with Fast Red chromogen, and positive IHC staining for spike antigen was visualized as granular brown color from 3,3′-diaminobenzidine (DAB) reagent.
(B) Representative in situ hybridization of an RNAScope control probe (left panels) and SARS-CoV-2 mRNA vaccine-specific probe (middle panels) within ipsilateral axillary core needle LN biopsies of female patients 7–60 days after second mRNA-1273 or BNT162b2 dose. Probe hybridization is indicated by red chromogen spots. IHC signal for spike antigen (right panels) is detected as granular brown staining.
(C) Quantification of SARS-CoV-2 mRNA vaccine-specific probe-staining GCs in vaccinated LN biopsies.
(D) Quantification of positive SARS-CoV-2 mRNA vaccine-specific probe spots per GC in vaccinee LNs. Error bars represent mean ± SEM.
(E) Spike-protein-positive GC quantification from IHC staining of vaccinee LNs.
(F) IHC staining for spike (lower right panel) and nucleocapsid (upper panels and lower left panel) antigens in representative sections of COVID-19 patient peribronchial LNs. Nucleocapsid detection in primary (upper right panel) and secondary (upper left panel) LN follicles.
(G) Due to the low frequency of detection of spike antigen in COVID-19 patient LNs, quantification is presented as the number of patients with positive staining in their LN specimens.
(H) Quantification of the number of COVID-19 patients with LN follicles positive for nucleocapsid IHC staining.
(I) Number and percentage of nucleocapsid-positive follicles by IHC in COVID-19 patient LNs. Error bars represent mean ± SEM.
(J) Spike concentration measured in plasma samples collected before and at several time points after BNT162b2 vaccination, with the red dotted line indicating the cutoff for positive.
(K) Spike concentrations were measured in plasma samples collected from BNT162b2 vaccinees on D0 (spike negative) or D28 (spike positive) spiked with different concentrations of recombinant spike protein. Black dotted line = cutoff for positive.
(L) Spike concentration measured in plasma samples collected from BNT162b2 vaccinees on D0, D21, D22/23, and D28 mixed with the same plasma sample collected from one BNT162b2 vaccinee on D1 (spike positive). Black dotted line = cutoff for positive.